GlassScriptPhysician profile
Marcella A Nole
NPI 1659335735
$7,840.90
in general payments reported to CMS, 2019-2025
28 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $784 · 2022: $1,614 · 2023: $1,966 · 2024: $1,516 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,412 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.60 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,117.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,371.85 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,285.25 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $611.14 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $353.40 | 2021-2025 | Entyvio |
| Madrigal Pharmaceuticals | $336.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $293.59 | 2021-2023 | Zeposia |
| Pfizer INC. | $258.44 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $153.70 | 2024 | |
| Phathom Pharmaceuticals, INC. | $144.24 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $94.06 | 2022-2024 | Dupixent |
| Genzyme Corporation | $90.33 | 2022-2025 | |
| Lilly USA, LLC | $81.23 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $76.31 | 2023-2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $71.94 | 2025 | Iqirvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $69.55 | 2022-2023 | Sutab |
| Celltrion USA INC. | $69.32 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ironwood Pharmaceuticals, INC | $66.60 | 2022-2024 | Linzess |
| Gilead Sciences, INC. | $53.10 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $45.71 | 2023 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $40.10 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $31.75 | 2022-2023 | |
| Organon LLC | $27.17 | 2023 | Hadlima |
| Qol Medical, LLC | $23.85 | 2021 | |
| Redhill Biopharma INC. | $22.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.57 | 2021 | |
| Shield Therapeutics INC | $19.33 | 2023 | Accrufer |
| Ultragenyx Pharmaceutical INC. | $12.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Nole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.